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Effect of Cognitive TherapyWith AntidepressantMedications
vs Antidepressants Alone on the Rate of Recovery
inMajor Depressive Disorder
A Randomized Clinical Trial
Steven D. Hollon, PhD; Robert J. DeRubeis, PhD; Jan Fawcett, MD; Jay D. Amsterdam, MD;
Richard C. Shelton, MD; John Zajecka, MD; Paula R. Young, PhD; Robert Gallop, PhD
IMPORTANCE Antidepressant medication (ADM) is efficacious in the treatment of depression,
but not all patients achieve remission and fewer still achieve recovery with ADM alone.
OBJECTIVE To determine the effects of combining cognitive therapy (CT) with ADM vs ADM
alone on remission and recovery in major depressive disorder (MDD).
DESIGN, SETTING, AND PARTICIPANTS A total of 452 adult outpatients with chronic or
recurrent MDD participated in a trial conducted in research clinics at 3 university medical
centers in the United States. The patients were randomly assigned to ADM treatment alone
or CT combined with ADM treatment. Treatment was continued for up to 42months until
recovery was achieved.
INTERVENTIONS Antidepressant medication with or without CT.
MAIN OUTCOMES ANDMEASURES Blind evaluations of recovery with amodified version of the
17-itemHamilton Rating Scale for Depression and the Longitudinal Interval Follow-up
Evaluation.
RESULTS Combined treatment enhanced the rate of recovery vs treatment with ADM alone
(72.6% vs 62.5%; t451 = 2.45; P = .01; hazard ratio [HR], 1.33; 95% CI, 1.06-1.68; number
needed to treat [NNT], 10; 95% CI, 5-72). This effect was conditioned on interactions with
severity (t451 = 1.97; P = .05; NNT, 5) and chronicity (χ
2 = 7.46; P = .02; NNT, 6) such that the
advantage for combined treatment was limited to patients with severe, nonchronic MDD
(81.3% vs 51.7%; n = 146; t145 = 3.96; P = .001; HR, 2.34; 95% CI, 1.54-3.57; NNT, 3; 95% CI,
2-5). Fewer patients dropped out of combined treatment vs ADM treatment alone (18.9% vs
26.8%; t451 = −2.04; P = .04; HR, 0.66; 95% CI, 0.45-0.98). Remission rates did not differ
significantly either as a main effect of treatment or as an interaction with severity or
chronicity. Patients with comorbid Axis II disorders took longer to recover than did patients
without comorbid Axis II disorders regardless of the condition (P = .01). Patients who
received combined treatment reported fewer serious adverse events than did patients who
received ADMs alone (49 vs 71; P = .02), largely because they experienced less time in an
MDD episode.
CONCLUSIONS AND RELEVANCE Cognitive therapy combinedwith ADM treatment enhances
the rates of recovery fromMDD relative to ADMs alone, with the effect limited to patients
with severe, nonchronic depression.
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T here is a growing consensus1 that simply reducing de-pressive symptoms (response) is not sufficient and thatfullnormalization(remission)shouldbethegoalofacute
treatment. Practitioners are encouraged to switch or aug-
ment treatments until remission is achieved or all reasonable
alternatives have been exhausted. Sustained remission (re-
covery) is better still, and it is recommended2 that patients in
remissioncontinue to receive treatmentuntil theypass thepe-
riod of risk for relapse.
Antidepressant medication (ADM) is the most common
treatment for depression3 and is especially recommended for
patientswhose condition ismore severe.4 One-third of all pa-
tients will achieve remission with any given ADM, but half of
these patients will experience relapse during continuation
treatmentbefore theyachieverecovery.5Cognitive therapy(CT)
is as efficacious as ADM alone,6 and combining the 2 in-
creases response rates, with estimates of the increase rang-
ing from 6% to 33%.7-11
Most randomized clinical trials do not reflect the aims of
personalizedmedicine.Randomizedclinical trials usually test
a single ADM delivered for a brief duration, whereas patients
in clinical practice can receive treatment for as long as neces-
sary with whatever medications are required to yield the de-
sired result.12 Similarly, CT is delivered in a brief time-limited
format in most randomized clinical trials, even though pa-
tientswithcomorbidAxis II disordersneed longer treatment.13
Studies inwhichpractitioners arenotpermitted toadapt treat-
ment to meet the needs of the patient likely underestimate
what could be achieved using the best clinical practice.14 We
sought to determine whether combining CT with ADM en-
hances recovery when treatment is personalized.
Methods
Patients
The study was conducted at outpatient clinics at the Univer-
sity of Pennsylvania, Philadelphia; RushMedical Center, Chi-
cago, Illinois; and Vanderbilt University, Nashville, Tennes-
see. Institutional review boards at the respective institutions
approved theprotocol, and an independent data safetymoni-
toring board monitored study implementation. Participants
were recruited frompersonswhosought treatment at the clin-
ics in these institutions. Written informed consent was ob-
tained prior to any research activity. Participants received fi-
nancial compensation for completing the assessments butnot
for the treatment. The Structured Clinical Interviews for
DSM-IVdiagnosis (Axis I andAxis II)wereused to establishdi-
agnostic eligibility.15,16
Thesamplecomprised452adultoutpatients. Inclusioncri-
teriawere (1)DSM-IVmajordepressivedisorder (MDD)17 either
chronic (episode duration ≥2 years) or recurrent (with an epi-
sode in the past 3 years if only the second episode), (2) 17-
itemHamiltonRating Scale for Depression (HRSD) score of 14
or more, (3) age 18 years or older, (4) English speaking, and
(5)willingandable toprovide informedconsent.Exclusioncri-
teria were (1) history of bipolar disorder or nonaffective psy-
chosis, (2) substance dependence in the past 3 months,
(3) DSM-IV Axis I disorders requiring nonprotocol treatment,
(4) DSM-IV Axis II disorders poorly suited to study treat-
ments (antisocial, borderline, and schizotypal), (5) suicide risk
requiring immediatehospitalization, (6)medical conditionpre-
cluding the use of study medications (including pregnancy),
(7) current medications that induce depression, or (8) man-
dated treatment or compensation issues.
Procedures
Figure 1depicts the studydesign andpatient flow.The sample
size was set to detect differences of 15% or greater (α = .05;
β = 0.20) based on previous findings.18 A total of 2097 poten-
tial participantswere screened inpersonorby telephone; 1178
were invited for diagnostic interviews. Of those, 452 patients
met all entry criteria andwere randomly assigned (1:1 ratio) to
receiveADMalone (n = 225)orADMplusCT (n = 227).Theproj-
ect statistician (R.G.) generated randomization schedules for
each site stratified on sex, marital status, symptom severity,
recurrence, chronicity, and comorbid Axis II disorder. Project
coordinators at each site were able to access these assign-
mentsonlyafter eachpatientwasscreened into theproject and
provided informed consent. Intake ran from July 24, 2002,
through February 22, 2006; the last patient completed con-
tinuation treatment in July 2009. (A 3-year follow-up will be
reported.)
Acute treatment lasted until the patient met the criteria
for remission, defined as 4 consecutive weeks of minimal
symptoms; continuation treatment lasted to the point of re-
covery, defined as another 26 consecutive weeks without re-
lapse. Patients did not need to maintain the symptom levels
required for remission to meet the criteria for recovery. Par-
ticipants who experienced relapse during continuation were
required tomeet remission criteria again before theywere eli-
gible tomeet thecriteria for recovery.Patientswhodidnotmeet
the symptomatic criteria for remission within 18 months of
treatmentwere removed fromthe studyand referred for other
treatment, as were patients who did not meet criteria for re-
coverywithin 36months. Patientswhomet only the sympto-
matic criterion for remissionatmonth 18 (or recoveryatmonth
36) continued treatmentuntil itwasdeterminedwhether they
alsomet the temporal criteria. Thus, up to 19monthswere al-
lowed for remission and up to 42 months for recovery.
Measures
The17-itemHRSD,19modified to include increases in sleep, ap-
petite, and weight,20 was used to assess depression severity.
The Longitudinal Interval Follow-up Evaluation (LIFE) was
used to provide retrospective assessments of diagnostic sta-
tus across time.21 Both instruments were conducted at least
biweekly through week 4, every 4 weeks through week 20 of
acute treatment, andevery8weeks thereafter through theend
of continuation treatment.Trained interviewersblind to treat-
ment condition conducted the evaluations. All evaluations
were recorded, and a subset was rated across sites to estab-
lish interrater reliability. An intraclass correlation coefficient
of 0.96was obtained for the 17-item totalHRSD score (n = 24);
majordepressiveepisodedesignationontheLIFEscaleyielded
a κ value of 0.80 (n = 12).22
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Outcome Criteria
Full remissionwasdefinedasHRSDscoresof8or less andLIFE
ratings of 2 or less for 4 consecutive weeks. After month 12,
these criteria were relaxed such that 4 weeks of HRSD scores
of 12 or lower or LIFE ratings of 3 or lower were sufficient to
meet the criteria for partial remission. Relapsewas defined as
2consecutiveweeksofHRSDscoresof 16ormoreorLIFEscores
of 5 or more. Serious adverse events (SAEs) were reported to
therespective institutional reviewboardsandto thedatasafety
monitoringboardas theyoccurred.Seriousadverseeventswere
defined as any untoward event that compromised the pa-
tient’s health including death for any reason, suicide at-
tempt, psychiatric ormedical hospitalization, and pregnancy
or motor vehicle crash while receiving study medications.
Treatment Procedures
Pharmacotherapy
A principle-based algorithm was implemented that could
involve up to 4 different classes of ADMs and any of the aug-
menting or adjunctive agents commonly used in clinical
practice. Dosages were raised as rapidly as possible and kept
at maximum tolerated levels for at least 4 weeks. Treatment
in patients who exhibited only a partial response was aug-
mented with additional medications, and treatment in those
who showed minimal response (or little additional response
following augmentation) was switched to another ADM.
Most patients were given multiple trials with easier-to-
manage selective serotonin reuptake inhibitors or serotonin-
norepinephrine reuptake inhibitors before treatment was
switched to more difficult-to-manage tricyclic antidepres-
sants or monoamine oxidase inhibitors. Patients who experi-
enced remission usually received the same medications
during treatment continuation, but the prescribing practi-
tioners were free to adjust the doses and augment or switch
medications as needed to forestall relapse. The goal was to
provide personalized antidepressant therapy using the best
clinical practice. These principles were followed in both
treatment conditions. A detailed account of the medications
Figure 1. Consolidated Standards for Reporting of Trials Diagram of Patient Flow Through the Study
2097 Individuals screened for eligibility
1178 SCID diagnostic interview
452 Randomized
726 Not randomized
381 Failed to come to interview
156 Screened out at interview
89 Did not meet depression criteria
2 Neither chronic nor recurrent
23 Bipolar disorder
5 Schizophrenia or other psychosis
19 Substance abuse
6 Other Axis I disorder
10 Borderline personality disorder
2 Schizotypal personality disorder
0 Antisocial personality disorder
1 Imminent suicide risk
1 Medical condition
7 Would not stop current treatment
4 Did not want medications
58 Declined study participation
118 Other reasons
919 Ineligible for interview
170 Time or schedule problems
40 Moved away or live too far
19 Sought other treatment
143 Did not meet depression criteria
17 Neither chronic nor recurrent
99 Bipolar disorder
17 Schizophrenia or other psychosis
86 Substance abuse last 3 mo
29 Other Axis I disorder
7 Borderline personality disorder
0 Schizotypal personality disorder
2 Antisocial personality disorder
10 Imminent suicide risk
38 Medical condition
55 Would not stop current treatment
47 Did not want medications
12 Wanted combined treatment
60 Declined study participation
2 Pregnant (or trying) or nursing
4 Legal or compensation issues
62 Other reasons
227 Allocated to combined treatment
165 Recovered
40 Excluded
29 Dropouts
1 Withdrawn
10 Terminated
22 Excluded
10 Dropouts
2 Withdrawn
10 Terminated
187 Remitted/entered continuation
158 Full
29 Partial
225 Allocated to medication alone
140 Recovered
55 Excluded
34 Dropouts
3 Withdrawn
18 Terminated
30 Excluded
22 Dropouts
1 Withdrawn
7 Terminated
170 Remitted/entered continuation
138 Full
32 Partial
MDD indicates major depressive disorder; SCID, Structured Clinical Interview for DSM-IV.15
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used is beyond the scope of this article and will be subse-
quently reported.
The protocol called for patients to meet with their pre-
scribingpractitionerweekly for the firstmonth,biweekly there-
after during acute treatment, and monthly during continua-
tion. The initial session lasted 30 to 45 minutes, with
subsequent sessions approximately 20 minutes. Ten board-
certifiedpsychiatristsand7psychiatricnursepractitionerswith
prescribing privileges provided pharmacotherapy (including
J.D.A. and J.Z.). Sessions followed the protocol developed by
Fawcett andcolleagues23 for theTreatmentofDepressionCol-
laborative Research Program. Dr Fawcett oversaw the train-
ing andprovided consultation throughout the study. Three of
us served as the medical directors and provided supervision
at the respective sites (J.D.A., R.C.S., and J.Z.). Pharmaco-
therapy sessions focused on (1) medication management in-
cluding education aboutmedications, dosage schedules, and
adverse effects; and (2) clinical management, including a re-
viewof thepatient’s functioning inmajor life spheres andbrief
supportive counseling.
Cognitive Therapy
Twelvedoctoral-levelpsychologists, 1psychiatrist, and1nurse
practitionerprovidedCT (includingP.R.Y.). The therapistsmet
weekly for 90 minutes at each site to review cases, with on-
site supervisionprovidedby3of theauthors (R.J.D., P.R.Y., and
S.D.H.). The therapists followed theproceduresoutlined in the
original treatment manual for CT of depression,24 aug-
mented when indicated for patients with comorbid Axis II
disorders.25 The protocol called for 50-minute sessions to be
held twiceweekly for at least the first 2weeks, at leastweekly
thereafter during acute treatment, and then at least monthly
during continuation. Therapists were free to vary the session
frequency to meet the needs of the patient.
Statistical Analysis
Survival analyses were used to model treatment outcomes.
In conventional survival analyses, censoring because of
attrition is assumed to be unrelated to treatment or patient
characteristics and therefore independent of time to the
event.26 However, when attrition precludes the occurrence
of the event, as it did in this trial, it is a competing risk that
can bias estimates of the time to remission or recovery.27 We
therefore adopted the subdistribution hazard model devel-
oped by Fine and Gray28 to account for the possible noninde-
pendence of the censoring mechanism. The weighted partial
likelihood estimation directly assesses the intervention and
moderation effects for the target event even in the presence
of a competing and possibly informative relationship
between multiple competing events. The basic model
included main effects for site, treatment, and their interac-
tion. Main effects and treatment interactions for each of the
stratification variables were estimated in the full models and
retained in the final models only if significant. All models
were implemented in SAS, version 9.3 (SAS Institute Inc)
using the algorithm developed by Zhang and Zhang29 for the
subdistribution hazard model. Significance was determined
using 2-tailed, unpaired t tests. To characterize the clinical sig-
nificanceof the findings,we computed thenumberneeded to
treat (NNT) ratio, a metric used in evidence-based medicine
to estimate the number of persons who would need to re-
ceive the intervention to produce 1 additional positive
outcome.30 Mantel-Haenszel χ2 analysis was used to test for
treatment differences in the frequency of relapses and SAEs.
Results
Baseline Characteristics
A total of 452 patients were randomized: 151 at the University
of Pennsylvania, 151 at Rush University, and 150 at Vanderbilt
University. Baseline HRSD score means did not differ signifi-
cantlyasa functionof treatmentconditionor site (overallmean
[SD], 22.1 [4.2]; range, 14-33). The Table gives descriptive sta-
tistics for thebaselinevariables.No significantdifferences be-
tween the conditions were observed in these variables, but
there were some significant between-site differences.
Attrition and Termination
Of the randomizedpatients, 102 (22.6%)didnotcomplete treat-
ment: 95 dropped out and 7 were withdrawn by the staff (ex-
cessivesubstanceuse, 5;manicepisode,2).Attritionwasnearly
twice as likely to occur during acute treatment (n = 67) than
during continuation (n = 35). Attrition rateswere lower in the
ADM plus CT group than in the ADM-alone group (18.9% vs
26.8%; t451 = −2.04; P = .04; hazard ratio [HR], 0.66; 95% CI,
0.45-0.98). Patientswith Axis II disordersweremore likely to
drop out irrespective of their condition (27.4% vs 18.4%;
t451 = 2.09;P = .04). Patientswhodidnot achieve remissionby
month 18 (n = 28) or recovery by month 36 (n = 17) were ter-
minated from the study. Termination rates did not differ sig-
nificantlyby condition (ADMplusCT,8.8%;ADMalone, 11.1%;
χ1 = 0.62; P = .43).
Remission
Remission rateswere high anddid not differ significantly as a
function of treatment (full remission of 63.6% for ADM plus
CT vs 60.3% for ADM alone by month 12; t451 = 0.57; P = .58;
and full or partial remissionof80.1% forADMplusCTvs 77.2%
for ADM alone by month 18; t451= 0.87; P = .38). Median time
to remission was shorter with ADM plus CT than with ADM
alone (week 33 vs week 38), but this difference also was not
significant.Patients in theADMplusCTgroupevidenced fewer
relapses than did patients in the ADM-alone group (71 re-
lapses in 48 patients vs 80 relapses in 54 patients, respec-
tively), but this difference was not significant.
Recovery
Recovery rateswere higherwithADMplus CT thanwithADM
alone(72.6%vs62.5%; t451 = 2.45;P = .01;HR, 1.33;95%CI, 1.06-
1.68;NNT, 10;95%CI, 5-72) and lower forpatientswithvs those
without comorbid Axis II disorders irrespective of treatment
condition (61.2% vs 73.5%; t451 = 2.81; P = .01; HR, 1.40; 95%
CI, 1.11-1.77).Themaineffectof treatmentonrecoverywascon-
ditionedon interactionswith severity (t451 = 1.97;P = .05;NNT,
5) and chronicity (χ2 = 7.46; P = .02; NNT, 6). There were no
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other significantmaineffects or interactionsof treatment con-
dition with the other stratification variables or with site (all
P > .05).
Figure2displays the severityby treatment interaction.Re-
covery rates for patientswith low-severityMDD (intakeHRSD
median, <22)were similar in the 2 conditions (72.9%vs 69.8%
[n = 221]; t220 = 0.58;P = .56;HR, 1.10; 95%CI, 0.80-1.51;NNT,
32;95%CI, 7-211). Forpatientswithhigh-severityMDD, the rate
was higher with ADM plus CT compared with ADM alone
(73.4% vs 54.3% [n = 231]; t230 = 3.25; P = .001; HR, 1.71; 95%
CI, 1.24-2.37; NNT, 5; 95% CI, 3-15). Patients with nonchronic
MDDalso evidenced a higher recovery ratewithADMplus CT
comparedwithADMalone (76.7%vs59.2%;n = 280; t279 = 3.47;
P = .001; HR, 1.69; 95%CI, 1.26-2.27; NNT, 6; 95%CI, 4-15). No
significant difference was observed in patients with chronic
MDD (63.2% with CT plus ADM vs 70.2% with ADM alone;
n = 172; t171 = −1.07; P = .28; HR, 0.82; 95% CI, 0.57-1.18; NNT,
−14.08; 95%, CI, –21 to –5).
We followedup this pattern of findingswith an investiga-
tion of the relationship between the 2moderators in their ef-
fect on treatment. The test of the 3-way interaction (severity
by chronicity by treatment) did not indicate a significant dif-
Table. Baseline Characteristicsa
Characteristic
No. (%) of Patients
Total
(N = 452)
Pennsylvania
(n = 151)
Vanderbilt
(n = 150)
Rush
(n = 151)
Combined Therapy
(n = 227)
ADM
(n = 225)
HRSD score, mean (SD) 22.1 (4.2) 21.9 (4.3) 22.3 (4.3) 22.0 (4.0) 21.9 (4.0) 22.2 (4.4)
Female sex 266 (58.8) 75 (49.7)* 96 (64.0)† 95 (62.9)† 130 (57.3) 136 (60.4)
Age, mean (SD), y 43.2 (13.1) 45.8 (13.9)† 44.4 (12.3)† 39.2 (12.2)* 43.3 (12.9) 43.0 (13.4)
Race/ethnicity
White 388 (85.8) 127 (84.1) 130 (86.7) 131 (86.8) 194 (85.5) 194 (86.2)
Hispanic 27 (6.0) 6 (4.0)* 6 (4.0)* 15 (9.9)† 17 (7.5) 10 (4.4)
College graduate 218 (48.2) 86 (57.0)† 57 (38.0)* 75 (49.7)* 118 (52.0) 100 (44.4)
Income <$40 000/y 265 (58.6) 86 (57.0) 95 (63.3) 84 (55.6) 137 (60.4) 128 (56.9)
Married or cohabitating 168 (37.2) 53 (35.1) 59 (39.3) 56 (37.1) 85 (37.4) 83 (36.9)
Unemployed 140 (31.0) 47 (31.1) 48 (32.0) 42 (27.8) 77 (33.9) 61 (27.1)
Chronic MDDb 159 (35.2) 53 (35.1)† 88 (58.7)‡ 18 (11.2)* 78 (34.4) 81 (36.0)
Recurrent MDDb 376 (83.2) 124 (82.1)*† 120 (80.0)* 132 (87.4)† 190 (83.7) 186 (82.7)
Age at onset, mean (SD), y 23.8 (12.7) 22.0 (13.1)* 24.0 (13.4)*† 25.5 (11.3)† 24.6 (13.0) 23.0 (12.4)
No. of episodes, mean (SD) 7.8 (18.0) 6.8 (11.4)* 3.4 (6.2)* 13.2 (27.5)† 7.4 (16.7) 8.2 (19.3)
Prior ADM 303 (67.0) 100 (66.2) 104 (69.3) 100 (66.2) 152 (67.0) 151 (67.1)
Melancholicb 179 (39.6) 48 (31.8)* 69 (46.0)† 62 (41.0)*† 88 (38.8) 91 (40.4)
Atypicalb 96 (21.2) 30 (19.9) 38 (25.3) 28 (18.5) 47 (20.7) 49 (21.8)
Other Axis I disorderb 226 (50.0) 63 (41.7)* 90 (60.0)† 76 (50.3)*† 114 (50.2) 115 (51.1)
Any Axis II disorderb 225 (49.8) 53 (35.1)* 79 (52.7)† 93 (61.6)† 113 (49.8) 112 (49.8)
Abbreviations: ADM, antidepressant medication; HSRD, Hamilton Rating Scale
for Depression; MDD, major depressive disorder; Pennsylvania, University of
Pennsylvania; Rush, Rush University; Vanderbilt, Vanderbilt University.
a When all 3 sites differ from one another, they each have a different symbol:
lowest (*), intermediate (†), and highest (‡). When the lowest site differs from
the other 2 sites and they do not differ from one another: lowest (*) and each
of the 2 highest (†). When the 2 lowest sites do not differ from each other but
each differs from the highest: each of the 2 lowest (*) and highest (†). When
the lowest site differs from the highest site but the intermediate site does not
differ from either of the other 2 sites: lowest (*), intermediate (*†), and
highest (†).
bAccording to DSM-IV criteria.
Figure 2. Time to Recovery as a Function of Severity by Condition
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ADM (n = 117)
CT + ADM (n = 114)
ADM (n = 108)
CT + ADM (n = 113) Recovery was defined as 6months
without relapse following remission.
A, Low-severity major depressive
disorder (MDD), defined as an HRSD
score of less than 22 at intake.
B, High-severity MDD, defined as an
HRSD score of 22 or greater at intake.
ADM indicates antidepressant
medication; CT+ ADM, cognitive
therapy combined with ADM;
HRSD, Hamilton Rating Scale for
Depression; and dashed lines, median
time to recovery (50th percentile).
a P < .001.
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ference, but itwas grosslyunderpowered.31We therefore con-
ducted an exploratory analysis to determine whether sever-
ityandchronicitycontributed independently to the increments
observedorwhether theeffectsofeachdependedontheother.
We divided the sample into 4 subgroups defined by severity
and chronicity and obtained a significant 4 (subgroup) × 2
(treatment) interaction (χ3, 10.41; P = .02). In both low-
severity subgroups, aswell as in thehigh-severity chronic sub-
group, small, nonsignificant treatment effects were obtained
(P = .32, P = .42, and P = .92, respectively). In the nonchronic
severe subgroup, thedifference in recovery ratebetweenADM
plus CT (n = 71) and ADM alone (n = 75) was large and signifi-
cant (81.3%vs51.7%;n = 146; t145 = 3.96;P = .001;HR,2.34;95%
CI, 1.54-3.57; NNT, 3; 95% CI, 2-5) and remained so after Bon-
ferroni correction. Figure 3 depicts treatment effects on re-
covery, conditioned on chronicity, among patientswithmore
severe depression.
Safety
Patients experienced fewer SAEs with ADM plus CT com-
pared with ADM alone (49 vs 71; χ1 = 5.76; P = .02). The larg-
est categories were psychiatric hospitalization (19 vs 29) and
medical hospitalization (22 vs 31). Seven patients made sui-
cide attempts: 3 in the ADMplus CT group (twice by 1 person)
and 4 in the ADM-alone group. Therewere no completed sui-
cides. Therewas no significant difference in the rate atwhich
those SAEs occurred once time to recoverywas taken into ac-
count.
Discussion
Combining CTwith ADM enhanced the rate of recovery com-
paredwith ADM alone in a sample of patients with chronic or
recurrentnonpsychoticMDDandminimal exclusions forother
psychiatric andmedical comorbidities. Themodest (10%) in-
crement observed is low in the range of comparable trials7-10
but similar to the one other study11 that also followed amore
flexiblemedication algorithm. Doing somay leave little room
for CT to enhance recovery.
The magnitude of this increment nearly doubled for pa-
tients with more severe depression or nonchronic MDD epi-
sodes, but therewas little evidenceof benefit for patientswith
less severeor chronicMDD.These findings are consistentwith
those fromearlier trials. Thase andcolleagues32 found thatpa-
tientswith severe recurrentdepressionwereparticularly likely
to benefit from combined treatment relative to psycho-
therapy alone, and Kocsis and colleagues11 found no advan-
tage forcombinedtreatment relative toalgorithm-guidedtreat-
ment among patientswith chronic depression. In the present
study, exploratory analyses suggested that this incrementwas
larger still in the one-third of the patients withMDD that was
both more severe and nonchronic. Patients with chronic de-
pression and those with nonchronic and less severe depres-
sion (eachapproximatelyone-thirdof the sample) showedevi-
denceof little increment fromcombiningCTwithADM. Itmay
be that only patients with more severe MDD need CT to be
added to ADMand that thosewith chronicMDDare unable to
benefit from its addition.
Moderators identified in the present investigation could
be used prescriptively to guide a more efficient allocation of
treatment resources.33Given thehighercostof combinedtreat-
ment, itmight be reserved for patientswithnonchronic,more
severe depression. Such a recommendationwould be consis-
tentwith thegoalsofpersonalizedmedicine;patientsaregiven
what they most need, and costly resources are reserved for
those likely tobenefit fromthem.Patientswith comorbidAxis
II disorders evidencedhigher rates of attrition and lower rates
of recovery than did those without comorbid Axis II disor-
ders irrespective of treatment condition. We had hoped that
using a versionof CT adapted to the specific needs of suchpa-
tients would boost response, but clearly more needs to be
done.25 Patients who received the combined treatment expe-
rienced fewer SAEs (includinghospitalizations) but largelybe-
Figure 3. Time to Recovery as a Function of Chronicity by ConditionWithin High Severity
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a P < .001.
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cause they spent less time inMDD episodes.34 The fact that 7
patients made suicide attempts and that 48 were hospital-
ized for psychiatric reasons indicates that we were providing
therapy for clinically representative patients.14
The studyhas strengths and limitations. TreatingMDD to
a fixed outcome rather than for a fixed duration and follow-
ing aprinciple-drivenalgorithmrather than limiting themedi-
cations used ismore representative of clinical practice than is
the typical approach used in randomized clinical trials. Limi-
tations include (1) the exclusion of patients with nonchronic
first-episodeMDD,whichprecluded theopportunity to test for
interactions involving chronicity and recurrence; (2) the ab-
sence of another psychotherapy or psychotherapy control, in
combinationwithmedications, to test for the specificity ofCT
in accounting for the combined treatment advantage; (3) the
absence of a psychotherapy-only condition, which limits the
generalizability of the findings to patients receiving CT with
concurrentADM; (4) the lackof blinding forpatients and treat-
ment providers to the condition, which may have contrib-
uted to the superiorityof combined treatment; and (5) the lack
of a formal cost-benefit analysis.
Moderation always implies differential mediation.35 Our
findings suggest that CT engages different mechanisms than
ADMbut that it likely does so only in some patients. Identify-
ing these mechanisms may suggest ways to enhance treat-
mentresponse.Futurecombinatorial trials should includecom-
parisons with CT alone to examine the viability of each
monotherapy, especially given evidence that CT effects per-
sist beyond the end of treatment.36
Conclusions
Cognitive therapy combined with medication treatment en-
hancedratesof recovery relative tomedicationsalone,with the
effect limited to patients with severe nonchronic depressions.
Combined treatment also reduced the frequency of severe ad-
verse events, but largely because it reduced time in episode.
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